CRNX News and Press, Crinetics Pharmaceuticals Inc. From 05/12/22

Crinetics Pharmaceuticals press release (NASDAQ:CRNX): Q1 GAAP EPS of -$0.73 misses by $0.17. Revenue of $3.13M misses by $2.07M. Unrestricted cash, cash equivalents and investments totaled $319.7 million as of March 31, 2022, compared to $333.7 million as of December 31, 2021. For further ...

Phase 1 Multiple-Ascending Dose Data for CRN04894 Expected in 2Q22 Paltusotine’s Phase 3 PATHFNDR Trials in Acromegaly Advancing Towards Anticipated Top-Line Data Readouts in 2023 Clinical Trial of CRN04777 in Congenital Hyperinsulinism Patients Planned to...

As a potential big winner, Crinetics Pharmaceuticals executes prudent corporate strategies that focus on orphan diseases and established biological pathways. The lead medicine (paltusotine) demonstrated strong efficacy in its Phase 2 (ACROBAT Edge) trial for acromegaly. I expect s...

Shares have fallen by 15% since my 2019 recommendation. I provide a recap of the bullish thesis and recent events. Endocrinology is a unique field where early-stage studies can achieve substantial degree of 'derisking' in phase 1 healthy volunteer studies. Management & develop...

SAN DIEGO, April 18, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced tod...

5 Top Biotech Stocks To Watch Today The stock market offers plenty of opportunities for investors. Some industries would still catch the attention of investors regardless of the broader market sentiment. A prime example would be biotech stocks . Now, why is that so? For starters...

Gainers: Kaleido Biosciences (KLDO) +114%. Antares Pharma (ATRS) +49%. Sierra Oncology (SRRA) +39%. HighPeak Energy (HPK) +29%. Biofrontera (BFRI) +30%. Turning Point Therapeutics (TPTX) +27%. Aterian (ATER) +25%. Hallador Energy (HNRG) +23%. Crinetics Pharmaceutical (CRNX) +20%. Exscientia (...

Crinetics Pharmaceuticals (NASDAQ:CRNX) has priced an underwritten follow-on offering of 5.63M shares of its common stock at a price to the public of $22.22/share for expected gross proceeds of ~$125.0M. All of the shares to be sold in the offering are to be sold by Crinetics. Offering is exp...

SAN DIEGO, April 12, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, announced today t...

Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) traded today at a new 52-week high of $41.00. So far today approximately 4.2 million shares have been exchanged, as compared to an average 30-day volume of 264,000 shares. Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is currently priced 2.4% a...